Warfarin News and Research

RSS

Warfarin is a drug that prevents blood from clotting. It belongs to the family of drugs called anticoagulants (blood thinners).

Drug-coated balloon restores blood flow in narrowed bare metal stent

A drug-coated balloon inserted in a narrowed bare metal stent is a promising therapy for restoring blood flow, according to research presented at the American Heart Association's Scientific Sessions 2011.

17 Nov 2011

Xarelto (rivaroxaban) shows success as blood thinner in acute coronary syndrome

A new anti-blood clotting drug – Xarelto (rivaroxaban) has shown clinical success. It may help people with “acute coronary syndrome” lower their risk of death, subsequent heart attack or stroke, a new study finds. Acute coronary syndrome is term that includes people with angina or prior history of heart attack.

15 Nov 2011

BIDMC researcher says improvement in survival rates best 'since introduction of aspirin'

An oral anti-clotting drug, when added to standard medical treatment for acute coronary syndrome, lowered the risk of death, heart attack or stroke an average of 16 percent, according to research presented at the American Heart Association's Scientific Sessions.

14 Nov 2011

GenMark Diagnostics third quarter revenues increase 90% to $1.3 million

GenMark Diagnostics, Inc. today reported financial results for the third quarter ended September 30, 2011.

10 Nov 2011

Janssen receives FDA approval for Xarelto to prevent stroke in people with AF

The U.S. Food and Drug Administration today approved the anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in people who have abnormal heart rhythm.

5 Nov 2011

Pradaxa for stroke treatment results in higher costs

Treating patients with the new blood thinning medication dabigatran (Pradaxa), instead of warfarin results in significantly higher per patient costs and higher net costs per stroke avoided, according to a new study by pharmacy benefit manager Prime Therapeutics (Prime).The study will be presented today at the Academy of Managed Care Pharmacy's Educational Conference in Atlanta, Ga.

21 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

FDA panel votes 9-2 in favor of new blood thinner drug

A new stroke preventer from Bayer and Johnson & Johnson – Xarelto moved one step closer to U.S. approval, but questions remained about restrictions on labeling and the need for more studies.

9 Sep 2011

Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

9 Sep 2011

FDA stalls the blood-thinner Xarelto’s approval citing inadequate evidence

The Food and Drug Administration (FDA) said in a staff report released today that “there is insufficient information about the drug to determine whether it is safe for use with its proposed labeling.” Their report questions its safety and effectiveness, saying a new study is needed.

6 Sep 2011

Microvisk introduces unique handheld device which monitors blood clotting status

Microvisk Technologies has introduced its unique handheld devices which monitor the blood clotting status of patients to the US market. Showcased at the prestigious American Association for Clinical Chemistry annual conference, the Microvisk devices attracted strong interest from distributors and potential partners ahead of clinical trials in major US medical centres this autumn and product launches in 2012.

31 Aug 2011

Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress

A phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban was associated with a two to four-fold increase in bleeding when added to dual antiplatelet therapy in patients following an acute coronary syndrome.

30 Aug 2011

Bristol Meyer Squibb’s new blood thinner drug for stroke prevention

Researchers find that an experimental anticlotting pill Eliquis is more effective than standard drug, warfarin, at preventing strokes in people with a heart condition that puts them at high risk of blood clots and stroke. The new drug also known as apixaban, cut the risk of stroke by 21% compared with warfarin in people with atrial fibrillation (AF). It lowered the risk of dying by 11%.

30 Aug 2011

Dabigatran etexilate superior to warfarin for stroke prevention in AF patients

New data from two RE-LY trial sub-group analyses show that dabigatran etexilate provides consistent benefits in stroke in atrial fibrillation (AF) compared to well-controlled warfarin, irrespective of whether patients use antiplatelet or other concomitant therapies, such as the anti-arrhythmics amiodarone or verapamil.

29 Aug 2011

ELIQUIS better than warfarin in reduction of stroke, major bleeding, and mortality

Bristol-Myers Squibb Company and Pfizer Inc. today announced the main results of the Phase 3 clinical trial ARISTOTLE, which evaluated ELIQUIS compared to warfarin for the prevention of stroke or systemic embolism in 18,201 patients with atrial fibrillation and at least one risk factor for stroke.

29 Aug 2011

Apixaban superior to warfarin in preventing stroke and systemic embolism

A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation.

29 Aug 2011

BIPI to launch dabigatran etexilate Phase II trial in patients with mechanical heart valves

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to launch RE-ALIGN, a global, Phase II trial evaluating the safety and pharmacokinetics of dabigatran etexilate in 400 patients who have mechanical heart valves.

26 Aug 2011

ICU patients less likely to renew prescriptions for chronic diseases after discharge

Patients often do not renew prescriptions for their chronic diseases after they are released from hospital.

25 Aug 2011

New technique can detach sugars from carrier molecule, reattach them to drugs

The surface of cells and many biologically active molecules are studded with sugar structures that are not used to store energy, but rather are involved in communication, immunity and inflammation.

22 Aug 2011

Arrythmia drug may work in stroke prevention: Study

The latest research has revealed that a new drug for treating people with an irregular heartbeat has fewer side effects than the standard treatment and is just as good at cutting the risk of stroke. Rivaroxaban, which is easier for people to take, is as effective as warfarin at preventing blood clots and thus lowering the risk of stroke for patients with atrial fibrillation say researchers.

15 Aug 2011

Warfarin News and Research

Further Reading

Drug-coated balloon restores blood flow in narrowed bare metal stent

Xarelto (rivaroxaban) shows success as blood thinner in acute coronary syndrome

BIDMC researcher says improvement in survival rates best 'since introduction of aspirin'

GenMark Diagnostics third quarter revenues increase 90% to $1.3 million

Janssen receives FDA approval for Xarelto to prevent stroke in people with AF

Pradaxa for stroke treatment results in higher costs

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

FDA panel votes 9-2 in favor of new blood thinner drug

Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban

FDA stalls the blood-thinner Xarelto’s approval citing inadequate evidence

Microvisk introduces unique handheld device which monitors blood clotting status

Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress

Bristol Meyer Squibb’s new blood thinner drug for stroke prevention

Dabigatran etexilate superior to warfarin for stroke prevention in AF patients

ELIQUIS better than warfarin in reduction of stroke, major bleeding, and mortality

Apixaban superior to warfarin in preventing stroke and systemic embolism

BIPI to launch dabigatran etexilate Phase II trial in patients with mechanical heart valves

ICU patients less likely to renew prescriptions for chronic diseases after discharge

New technique can detach sugars from carrier molecule, reattach them to drugs

Arrythmia drug may work in stroke prevention: Study

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News